Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face.
This trial will evaluate the safety, tolerability and preliminary efficacy of ATI-50002 Topical applied twice daily in 24 adult subjects with non-segmental vitiligo of the face. This 24-week trial will be conducted at three investigational centers within the US.
"This trial is the first step in evaluating the potential clinical benefit of ATI-50002 Solution in treating patients with non-segmental vitiligo of the face," said Dr. Stuart Shanler, Chief Scientific Officer of Aclaris. "This is an important step forward in understanding the clinical utility of our JAK program in patients with vitiligo."